S. Peter Kang
Research Subjects
S. Peter Kang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Antoni Ribas
Department of Medicine, Division of Hematology and Oncology, University of California, Los Angeles, Los Angeles, USA
2 shared publications - Adil Daud
Department of Medicine University of California San Francisco California USA
1 shared publication - Alfonsus J. M. van Den Eertwegh
Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands
1 shared publication - Andrew Albright
Merck & Co. Inc., Kenilworth, New Jersey, USA
1 shared publication - Andrey Loboda
Merck & Co., Inc. 7 Boston, MA
1 shared publication - April K. S. Salama
Duke Cancer Institute, Durham, NC
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 26 June 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (8) , 2930-2940
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Programmed death-1–directed (PD-1–directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti–PD-1 therapies, including pembrolizumab. However, whether quantifying T cell–inflamed microenvironment is a useful pan-tumor determinant of PD-1–directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell–inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell–inflamed GEP contained IFN-γ–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell–inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
- 26 June 2017
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 127 (8) , 2930-2940
Top Cited PapersOpen AccessIFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Programmed death-1–directed (PD-1–directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti–PD-1 therapies, including pembrolizumab. However, whether quantifying T cell–inflamed microenvironment is a useful pan-tumor determinant of PD-1–directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell–inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell–inflamed GEP contained IFN-γ–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell–inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
- Open Access
- 1 November 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 67, 46-54
Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
- 1 November 2016
- Published by Elsevier in European Journal of Cancer
- Vol. 67, 46-54
Open AccessHealth-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma